Integrating Immunotherapy with Locoregional Treatment in Hepatocellular Carcinoma: Mechanistic Insights and Emerging Clinical Strategies

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer worldwide and the third leading cause of cancer-related mortality. Chronic viral hepatitis and metabolic liver disease are major contributors to its development. Many patients present with intermediate or advanced disease, for which treatment selection depends on tumor burden, vascular involvement, liver function, performance status, and multidisciplinary assessment. This review evaluates clinical evidence for combining locoregional therapies, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), thermal ablation, and transarterial radioembolization (TARE), with immune checkpoint inhibitors and antiangiogenic agents. In the phase III LEAP-012 trial, lenvatinib plus pembrolizumab with TACE improved median progression-free survival (PFS) compared with TACE alone (14.6 versus 10.0 months; hazard ratio 0.66), while the interim overall-survival (OS) difference was not statistically significant. Grade 3 or higher treatment-related adverse events were more frequent with the triplet regimen (71% versus 32%). EMERALD-1 also reported a PFS benefit for durvalumab plus bevacizumab with TACE, whereas mature OS benefit has not been established. Evidence for TACE-based combinations is more developed than evidence for HAIC-, ablation-, or TARE-based combinations, many of which remain investigational or are supported mainly by nonrandomized studies. Proposed mechanisms include immunogenic cell death, tumor-antigen release, changes in immune-checkpoint signaling, and vascular remodeling. Clinical implementation requires careful patient selection, preservation of hepatic reserve, monitoring for cumulative toxicity, and consideration of quality of life. Ongoing randomized trials, biomarker research, and precision-treatment approaches are expected to clarify which patients benefit from these combinations and how treatment should be sequenced.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-18
DOI
https://doi.org/10.1021/acsomega.6c11141
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrating Immunotherapy with Locoregional Treatment in Hepatocellular Carcinoma: Mechanistic Insights and Emerging Clinical Strategies

Raghvendra Ashok Bohara, Harekrishna Roy, Poonam Lal, Jitendra Patel
2 links
ACS Omega
Hepatocellular Carcinoma Treatment and Prognosis
article

Integrating Immunotherapy with Locoregional Treatment in Hepatocellular Carcinoma: Mechanistic Insights and Emerging Clinical Strategies

Raghvendra Ashok Bohara, Harekrishna Roy, Poonam Lal, Jitendra Patel
article en

Abstract

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer worldwide and the third leading cause of cancer-related mortality. Chronic viral hepatitis and metabolic liver disease are major contributors to its development. Many patients present with intermediate or advanced disease, for which treatment selection depends on tumor burden, vascular involvement, liver function, performance status, and multidisciplinary assessment. This review evaluates clinical evidence for combining locoregional therapies, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), thermal ablation, and transarterial radioembolization (TARE), with immune checkpoint inhibitors and antiangiogenic agents. In the phase III LEAP-012 trial, lenvatinib plus pembrolizumab with TACE improved median progression-free survival (PFS) compared with TACE alone (14.6 versus 10.0 months; hazard ratio 0.66), while the interim overall-survival (OS) difference was not statistically significant. Grade 3 or higher treatment-related adverse events were more frequent with the triplet regimen (71% versus 32%). EMERALD-1 also reported a PFS benefit for durvalumab plus bevacizumab with TACE, whereas mature OS benefit has not been established. Evidence for TACE-based combinations is more developed than evidence for HAIC-, ablation-, or TARE-based combinations, many of which remain investigational or are supported mainly by nonrandomized studies. Proposed mechanisms include immunogenic cell death, tumor-antigen release, changes in immune-checkpoint signaling, and vascular remodeling. Clinical implementation requires careful patient selection, preservation of hepatic reserve, monitoring for cumulative toxicity, and consideration of quality of life. Ongoing randomized trials, biomarker research, and precision-treatment approaches are expected to clarify which patients benefit from these combinations and how treatment should be sequenced.

ACS Omega
SRM University, Andhra Pradesh (IN), Dr. D.Y. Patil Vidyapeeth, Pune (IN)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon